Breast Cancer -- Where Are We? {#S1}
==============================

Breast cancer is the leading cause of cancer-related deaths in women worldwide ([@B9]). It is a heterogeneous disease ([@B91]), commonly separated into Luminal A (LumA), Luminal B (LumB), epidermal growth factor receptor ERBB2/HER2-overexpressing (HER2+), basal epithelial-like (BL) based on gene expression profiles ([@B108]). Breast cancer is currently treated with surgery, radiotherapy, cytotoxic chemotherapy and/or targeted therapies to eradicate viable cancer cells ([@B33]).

LumA and LumB breast cancers are both estrogen receptor (ER)-positive ([@B108]). Deregulated ER signaling is associated with cancer hallmarks ([@B43]). For instance, ER target genes like cyclin-dependent kinase (CDK) 1 or the kinase Src promote cell proliferation, invasion and epithelial--mesenchymal transition (EMT) ([@B110]; [@B104]). LumB cancers have high expression of the proliferation marker Ki67, which correlates with increased risk of developing distant metastases ([@B19]), and reduced expression of the progesterone receptor (PR) ([@B14]), which shifts gene expression toward more tumorigenic genes ([@B87]). LumA and LumB tumors are treated using ER antagonists (e.g., tamoxifen), aromatase inhibitors and selective estrogen receptor degraders (e.g., fulvestrant). However, therapeutic resistance may arise through loss of ER expression, mutations in ER or overexpression of alternative breast cancer-driving pathways such as ERBB1/EGFR ([@B38]; [@B17]; [@B76]). To overcome resistance to traditional ER antagonists targeted therapies against phosphoinositide 3-kinases (PI3K), mammalian target of rapamycin (mTOR), and CDK4/6 have recently been proven beneficial in the clinical setting ([@B5]; [@B63]; [@B94]).

HER2 + breast cancers overexpress ERBB2/HER2 ([@B54]) which promotes proliferation by regulating CDKs and Cyclins ([@B113]). Additionally, HER2 dimerization with EGFR induces activation of mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinases (JNK), and phosphoinositide phospholipase C (PLCγ) signaling pathways resulting in increased cell proliferation, migration and apoptosis resistance ([@B81]). HER2 + breast cancers are treated with targeted agents such as trastuzumab, pertuzumab, and neratinib. Trastuzumab is an antibody which inhibits HER2 dimerization, promotes natural killer cell recruitment to tumors and stimulates ubiquitin-dependent HER2 degradation ([@B125]; [@B82]; [@B105]; [@B121]). Therapeutic resistance to trastuzumab occurs via HER2 dimerization with other ERBB family members or constitutive HER2 activation ([@B125]).

BL breast cancers do not generally express ER, PR or HER2 ([@B85]), like triple negative breast cancers (TNBCs) ([@B69]). BLs are highly heterogeneous and include basal-like1-2, claudin-low, and immunomodulatory subgroups ([@B40]). BLs have a highly proliferative and invasive phenotype with high risk of relapse in early breast cancer ([@B31]). BLs are typically treated by chemotherapy and radiotherapy ([@B127]) although recent advances have led to novel treatment opportunities for BL cancer patients. For instance, immunomodulatory BLs can be treated with immune checkpoint programed cell death protein 1 (PD-1) and poly (ADP-ribose) polymerase (PARP) inhibitors ([@B82]; [@B105]; [@B121]).

Two major challenges in breast cancer treatment are therapeutic resistance and the formation of metastasis to secondary sites (lung, bone, lymph nodes, brain, and liver) inevitably leading to patient mortality ([@B86]). As 10 year survival for metastatic breast cancer patients remains below 5% ([@B62]) and response to targeted therapies varies from 15 to 40% for all subtypes ([@B4]; [@B44]) the need for novel therapeutic options for breast cancer patients remains a priority.

Here, we will describe several models that have contributed to knowledge of breast cancer biology and the repertoire of currently available therapeutic targets. Thereafter, we will introduce system biology-based approaches and finally discuss how their integration with traditional models is revolutionizing breast cancer translational research.

Models to Study Breast Cancer {#S2}
=============================

Cell Lines {#S2.SS1}
----------

Breast cancer has been traditionally studied using immortalized cell lines derived from patient samples ([@B49]) which are easy and inexpensive to grow. These cell lines express biomarkers of the different molecular subtypes of breast cancer ([@B22]) and recapitulate some parent tumor characteristics including drug responses ([@B49]) and transcriptomic profiles ([@B90]). Cell lines have enabled major discoveries in breast cancer research, such as the identification of oncogenes ([@B29]) and drivers of metastatic tropism ([@B86]). However, breast cancer cell lines have increased gene copy number variations compared to primary tumors ([@B65]), lack the *in vivo* microenvironment ([@B122]), and do not maintain primary tumor heterogeneity ([@B22]; [@B73]) ([Figure 1A](#F1){ref-type="fig"}).

![Models and methods to study breast cancer. Summary of the advantages (left column) and disadvantages (middle column) of existing breast cancer models **(A--D)** and 'omics technologies **(E)** to study breast cancer. Right column reports a brief summary of how different methods and models have contributed to major discoveries in the field of breast cancer.](fcell-07-00395-g001){#F1}

Organoids {#S2.SS2}
---------

Organoids are three dimensional (3D) cell cultures which mimic healthy tissues and cancer lesions ([@B132]). Organoids are usually grown in matrices such as Matrigel^TM^, collagen or peptide hydrogels which aim to recapitulate the breast microenvironment ([@B25]). The group of Mina Bissel in the '80s began to investigate how organoids were a better model for studying breast tissue compared to 2D cell culture ([@B129]). More recently, primary and metastatic organoids have been developed which accurately recapitulate parent tumor characteristics including histopathology, genomic abnormalities and drug responses ([@B103]). Organoids are easy to modify, can be propagated for up to 3 months ([@B32]), and allow drug screening ([@B28]). Recently, the issue of availability of primary patient samples for laboratories without access to biobanks has been solved by the creation of living biobanks of frozen organoids ([@B28]). Organoids can be used as models to study different breast cancer subtypes and to identify potential novel therapeutic targets. Organoid are better models than 2D cultures to analyze drug response due to a more representative microenvironment and selection for stem-like cells, like those responsible for metastatic initiation ([@B119]; [@B53]). Despite these promising characteristics for breast cancer translational research, organoids lack components of the *in vivo* microenvironment and may suffer for counterselection of hyperproliferative cells ([@B37]; [@B130]) ([Figure 1B](#F1){ref-type="fig"}).

Genetically Engineered Mouse Models (GEMMs) and Syngeneic Mouse Models (SMMs) {#S2.SS3}
-----------------------------------------------------------------------------

*In vivo* modeling of breast cancers generally entails inducing oncogene expression (e.g., *Erbb2*) or knocking out a tumor suppressor gene (e.g., *p53*) in mice. Examples include the mouse mammary tumor virus (MMTV) promoter-driven or the 4T1-based SMMs ([@B48]). GEMMs include a natural (mouse) microenvironment and immune system, and partially mimic all human subtypes save luminal cancers ([@B95]; [@B48]). However, GEMMs involve extensive costs and breeding time, often express supra-physiological levels of the transgene, and can be genetically different compared to their human counterpart ([@B95]). Only 16 of the 30 most commonly mutated genes in human breast cancers were found to be mutated in a panel of metastatic GEMMs and SMMs ([@B133]). Although SMMs have higher mutational burden in metastases than in primaries like human breast cancers ([@B133]; [@B136]), GEMMs and SMMs rarely mimic clinical metastasis ([@B48]). In spite of these pitfalls, GEMMS have been instrumental in generating insights into breast cancer biology -- e.g., determining that BRCA1 mutant tumors derive from luminal progenitor rather than basal cells ([@B88]) and in testing novel drugs combinations ([@B56]) ([Figure 1C](#F1){ref-type="fig"}).

Patient-Derived Xenografts (PDXs) {#S2.SS4}
---------------------------------

Patient-derived xenografts (PDXs), which involve injection of human cancer cells either orthopically in the mouse mammary fat pad or subcutaneously into immunocompromised mice, provide an *in vivo* alternative to GEMMs ([@B47]; [@B48]). They have helped address clinically relevant questions including the contribution of heterogeneity to, and the mechanism of, drug resistance ([@B11]). PDXs can be passaged in different mice allowing expansion of patient tissue whilst still maintaining 'omics profiles of the patient tumor; and they spontaneously metastasize ([@B24]; [@B26]). Drawbacks for the use of PDXs include the selection of more aggressive cells within the patient sample and the use of immunocompromised mice to prevent tumor rejection. Developing mice with humanized immune systems can help to address this problem ([@B45]), as recently shown for a metastasis model ([@B100]) ([Figure 1D](#F1){ref-type="fig"}).

In conclusion, choosing the correct model to study breast cancer depends on several factors including the biomedical question, sample availability, costs, etc. ([Figure 1](#F1){ref-type="fig"}). We envision that future interdisciplinary research will be based on a combination of different models to identify and validate new therapeutic targets for breast cancer treatment with the advent of next generation sequencing and more robust instrumentation, 'omics approaches, like genomics and proteomics, are becoming more accessible and are increasing the information that can be obtained from breast cancer models. Thus, 'omics approaches applied to the combination of different models will provide molecular information on a global scale and will identify novel targets.

System Biology Approaches to Study Breast Cancer {#S3}
================================================

System biology based on 'omics approaches and network science are becoming popular in cancer research ([@B77]), despite high costs in terms of sample handling, instrumentation, and time for data analysis. Integrating 'omics approaches allows the unbiased analysis of the whole genome, transcriptome, proteome, or metabolome starting from different types of samples ([Figure 1E](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

###### 

A selection of single- and multi-'omics-based breast cancer studies that have contributed to major discoveries in the field of breast cancer research where method strengths and weakness are reported.

  **Study**   **Topic area**                             **'Omics approaches**   **Method strengths**   **Method weaknesses**   **Major discoveries**                                                                                                                                                                                                                                                                                                                                                                                                                     
  ----------- ------------------------------------------ ----------------------- ---------------------- ----------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B91]      Novel Breast Cancer Drivers                ×                                                                                              The whole genome sequence can be determined relatively cheaply in less than a week                                                                                                               Sequences must be read many times to account for inaccuracies in sequencing analyzers                                                                                                                            Five novel cancer genes were identified. A total of 93 genes were suggested to contain breast cancer driver mutations
  [@B98]      Breast Cancer Risk                                                                                                ×                       This technique is dependent on serum samples which are far easier to obtain than biopsies needed for other 'omics techniques                                                                     Controlling patient diet is very difficult                                                                                                                                                                       Three metabolites were found to be associated with increased breast cancer risk
  [@B118]     Novel Therapeutic Targets                  ×                       ×                                                                      Combining DNA and RNA sequencing allows mutations to be connected to chromatin remodeling and gene expression                                                                                    RNA integrity is compromised by the process of formalin fixing due to cross-link formation                                                                                                                       RET and HER2 were found to be potential therapeutic targets for breast cancer brain metastases
  [@B52]      Novel Therapeutic Targets                  ×                       ×                      ×                                               Proteomic isobaric labeling methods allow multiple samples to undergo relative quantification reducing variability                                                                               Large amounts of starting protein is required for phospho- proteomics. Also proteomic labeling reagents are very expensive                                                                                       Novel therapeutic targets previously undiscovered at the genomic, transcriptomic or proteomic level were identified at the level of the phosphoproteome in PDX models
  [@B80]      Informing Clinical Therapeutic Decisions   ×                       ×                                                                      When tumor cell population is low in a biopsy, targeted sequencing of known cancer genes can still be used to search for actionable targets without having to purify the epithelial population   Extensive analysis is required to determine if a mutation is actionable. Also biopsies are often sent to pathologists before freezing so the molecular profile may be changed by the time the tissue is frozen   The treatment of 199 patients was based on an actionable genomic alteration which was found using DNA and RNA sequencing In 33% of patients. progression-free survival was significantly increased and in 11% there was objective response
  [@B83]      Breast Cancer Signaling                    ×                                              ×                                               In situations where mutations produce unpredictable consequences, e.g., altering splice variants, proteogenomics can identify single amino acid variants and link these to mutations             Proteins which are missing in one or more replicates of a proteomic experiment are often excluded despite the fact the protein may have been present below the detection threshold                               A number of highly phosphorylated kinases were identified that were not seen as potential therapeutic targets at the genomic level. Also the impact of mutations was traced to the signaling level to identify therapeutic targets, e.g., CETN3 loss was associated with EGFR upregulation. highlighting how this loss could be druggable
  [@B59]      Breast Cancer Subtypes                     ×                       ×                      ×                       ×                       Integrating 'omics technologies allowed the mRNA- based subtypes to be expanded to a more clinically useful resource                                                                             Tumors are heterogenous and so 'omics data from one part of a biopsy may not be representative of the whole tumor                                                                                                Breast cancer subtypes ([@B108]) were validated at a multi-omic level. Basal-like tumors were separated into two clusters that could inform therapeutic decisions

G, genomics; T, transcriptomics; P, proteomics; M, metabolomics.

Genomics {#S3.SS1}
--------

Next generation sequencing (NGS) allows rapid and relatively inexpensive DNA sequencing covering the whole genome ([@B93]). Genomic approaches helped redefine breast cancer subtypes ([@B12]), identify mutational landscapes ([@B111]) or single nucleotide polymorphisms (SNPs) as a biomarker of breast cancer susceptibility ([@B84]) or therapeutic response ([@B64]). NGS has also facilitated the discovery of breast cancer driver mutations ([@B91]), tumor heterogeneity ([@B135]) and novel therapeutic targets in metastatic disease ([@B7]). Finally, single-cell analysis allowed the study of breast cancer stem cells ([@B66]). However, accurate genomic analysis requires large numbers of sequence reads which increases both time and cost.

These discoveries demonstrate the potential for genomics to transform breast cancer treatment ([@B42]). For instance, genomics helped identify patients for clinical trials ([@B21]) or high risk individuals through mutation screening in breast cancer susceptibility (BRCA) 1--2 genes ([@B30]) and contributed to therapeutic decision making ([@B116]; [@B6]). As an invaluable resource for researchers, the Catalogue of Somatic Mutations in Cancer (COSMIC) has compiled genomic data from breast cancer patient samples and correlated them to cellular functions and drug resistance ([@B35]). Finally, genomic analysis for the early identification of tailored therapy for cancer patients has been made possible with the development of the Cancer Genome Atlas (TCGA)^[1](#footnote1){ref-type="fn"}^. We envision that TCGA and COSMIC databases will revolutionize cancer patient diagnosis and treatment ([@B1]). This is already being realized in the MOSCATO trial where druggable genomic aberrations were identified and targeted in patients ([@B80]).

In addition, cell-free/circulating tumor DNA (cf/ctDNA) can be useful in monitoring clonal evolution and residual tumor presence following treatment ([@B10]). However, as ctDNA usually comprises 180--200 bp fragments from apoptotic cells, there are varying degrees of success in identifying useful biomarkers with high sensitivity ([@B106]). Despite this, serial screening for mutations in ctDNA has allowed metastatic detection 8 months before clinical presentation ([@B39]).

Together with genomics, epigenomics (the study of DNA modifications and their impact) is also providing novel markers for breast cancer prognosis ([@B23]) and for detection of metastasis ([@B68]). Epigenomics has begun to illuminate the link between menopause and lifestyle factors with breast cancer risk and so may provide prognostic utility in future ([@B20]).

Transcriptomics {#S3.SS2}
---------------

Transcriptomics uses microarrays, which quantify a set of predetermined sequences, and RNA sequencing (RNA-Seq), which uses high-throughput sequencing to capture all sequences to determine the quantity of a transcript ([@B75]). These approaches have been used to classify breast cancer molecular subtypes in cell lines ([@B90]) and patient-derived samples ([@B131]; [@B58]), to compare primary breast cancers and their metastases ([@B118]), and to visualize phenotypic features of breast cancer cells in 3D culture ([@B114]). In addition, transcriptomics is allowing immune cell characterization in normal breast and tumor tissue ([@B16]; [@B2]), potentially providing a mechanism to inform immunotherapeutic decisions.

As transcriptomics does not provide information on the expression, post-translational modifications (PTMs), or activation status of proteins it is less informative than proteomics for novel therapeutic target discovery. Recent advancements in single cell analysis may open a new era in breast cancer research to identify drivers, biomarkers, and novel therapeutic targets ([@B50]).

In the clinic, analysis of mRNA expression of gene subsets, involved in ER signaling, HER2 signaling, proliferation and invasion, is already used to predict relapse and determine whether patients would benefit from neoadjuvant chemotherapy ([@B120]). Furthermore, as patients with elevated expression of a migratory mRNA signature had worse overall survival than those with a proliferative mRNA signature and so responded significantly better to chemotherapeutics that targeted the cytoskeleton ([@B89]) transcriptomics has the potential to inform chemotherapeutic decisions in future.

As patient tumor biopsies are typically formalin fixed and paraffin-embedded (FFPE), a preservation procedure that reduces RNA integrity ([@B123]), fresh frozen tissue collection should become the standard procedure for mRNA expression to inform clinical decisions.

Proteomics {#S3.SS3}
----------

Proteomics studies the expressed proteome and its PTMs by mass spectrometry (MS), protein microarrays, and, more recently, mass cytometry. Advances in samples handling, instrumentation, and data analysis now provide unprecedented insights into the abundance and function of the (modified) proteome ([@B27]). Proteomics can assess tissue or blood samples, thus lending itself to clinical applications ([@B78]). For instance, specific serum biomarkers have been discovered by proteomic studies ([@B70]; [@B99]), potentially providing an early diagnosis signature ([@B102]). Correlation between RNA or gene copy number with protein expression is rather low ([@B83]; [@B59]) thus analyzing the patient proteome holds promise for identifying novel preventative or therapeutic targets not previously identified at the genomic or transcriptomic level. This idea is supported by the fact that currently used anti-breast cancer drugs predominantly act against proteins.

MS-based proteomics has been used to characterize cell lines ([@B51]), to reveal novel layers of breast cancer classification ([@B117]; [@B134]), and to identify proteins involved in drug resistance ([@B74]). Furthermore, phosphoproteomics that identify phosphorylated proteins ([@B124]) has been used to connect somatic mutations to signaling (proteogenomics) ([@B83]), to identify kinases signatures in TNBC ([@B137]), and to map drug targets for personalized treatments ([@B96]). These discoveries have diagnostic and prognostic potential which is worth further exploring and implementing in the clinic when phosphoproteomics methods will become common practice.

An alternative to MS-based proteomics is provided by mass cytometry where single cells are probed with metal ion-labeled antibodies and then samples are analyzed by time-of-flight mass spectrometry ([@B67]). In breast cancer research this technology has been recently used to identify cell types and immune infiltrates within a tumor ([@B126]). However, this method remains limited by antibody availability. Similarly to transcriptomics, phosphoproteomics is also limited by the availability of fresh frozen tissue as the phosphoproteome is substantially altered by FFPE preservation ([@B128]).

In conclusion, analyzing the proteome and phosphoproteome of patients at different breast cancer stages will help identify signatures for personalized treatments, ideally starting from liquid biopsies. In future proteomics may be used to follow the response to treatment by analyzing changes in patient proteome so to adapt the therapeutic plan.

Metabolomics {#S3.SS4}
------------

Metabolomics is the system-wide identification of endogenous metabolites from bodily fluids in a targeted or unbiased manner ([@B107]). Metabolomics has been used to correlate changes in metabolism with proliferation rate in breast cancer cells ([@B57]), to cluster tumor subtypes ([@B46]), to analyze the lipids content in breast cancer cells ([@B72]), and to correlate nutrients with breast cancer risk ([@B98]). More recently, this approach has begun paving the way for the identification of metabolic-state specific biomarkers for breast cancer diagnosis ([@B55]). Therefore, metabolomics will allow further insights into correlation between metabolism, epigenomic and proteomic alterations and breast cancer progression or treatment.

Data Integration {#S3.SS5}
----------------

The contribution of each aforementioned 'omics technology to the understanding of breast cancer biology and to the discovery of novel targets or biomarkers has been substantial. Integrating these approaches is predicted to be even more powerful ([@B13]; [@B77]) ([Table 1](#T1){ref-type="table"}) For instance, a genomic/transcriptomic/proteomic combined approach has confirmed the existence of the known molecular subtypes (LumA, LumB, HER2+, and BL) of breast cancer ([@B12]) as well as allowing identification of novel therapeutic targets in PDX models ([@B52]). Recently, a comprehensive analysis of clinical, genomics, and transcriptomics data has uncovered the TNBC landscape ([@B58]). Proteogenomics has challenged the way in which somatic mutations contribute to signaling changes ([@B83]), highlighting the need of both these analyses to confirm the therapeutic importance of a genetic alteration. For instance, patients lacking HER2 amplification were found to have enriched HER2 signaling ([@B96]), underlining the importance of analyzing changes in signaling to plan the correct therapeutic approach. With the development of single cell analysis in genomics, transcriptomics and proteomics ([@B71]; [@B50]; [@B79]; [@B126]) there are opportunities to better understand breast cancer heterogeneity and the role of the microenvironment. Finally, it would be fascinating to integrate 'omics approaches with radiomics (quantitative information from digital images) ([@B97]) and with imaging-based mass spectrometry that is rapidly changing the field of spatial proteomics ([@B61]) to guide patient-specific therapy or patient stratification.

'Omics Approaches Applied to Existing Breast Cancer Models {#S4}
==========================================================

Integrating 'omics approaches with traditional methods has already helped underline the validity of some of the models, for example, highlighting that omics profiles are maintained in PDX models through multiple passages ([@B138]). Multiomics technologies have also facilitated novel discoveries in existing models ([@B13]). A combination of genomics, transcriptomics and proteomics has elucidated drivers of mesenchymal-to-epithelial transition in 2D culture ([@B8]). Transcriptomics in GEMM and SMM-derived cell lines allowed identification of differentially regulated genes and their contribution to metastases ([@B133]) Transcriptomics and proteogenomics in PDXs have finally helped to profile gene/proteins expression to identify novel targets ([@B52]).

'Omics technologies have not only improved the power of traditional models in breast cancer research, but also revolutionized the analysis of patient samples, making them an indispensble tool in translational studies. Integration of 'omics approaches requires powerful computational and statistical methods to analyze and interpret the vast quantity of available data, for instance combining linear mathematical models with machine learning and network science principles ([@B77]). This requires collaboration between cancer scientists, computational biologists and medical statisticians to create robust methods to gain insights into cancer biology and to inform clinical trials and personalized therapeutic regimes.

Conclusion and Perspectives {#S5}
===========================

With 'omics technologies applied to patient samples becoming robust, our understanding of the mechanisms driving breast cancer and the discovery of novel biomarkers and therapeutic targets have improved significantly over the last few years ([@B13]; [@B77]). For instance, the use of molecular assays, including OncotypeDx and MammaPrint in the clinic is based on advancements in genomic technologies ([@B41]; [@B120]). Transparent sharing of 'omics data in databases like COSMIC ([@B36]), PRIDE ([@B60]) and others ([Table 2](#T2){ref-type="table"}) will allow unbiased analysis of available data by different groups to find previously unnoticed potential genes or proteins of interest as biomarkers or therapeutic targets.

###### 

A selection of 'omics data repositories built for data sharing and to support research questions ([@B3]; [@B34]; [@B92]; [@B109]; [@B115]; [@B18]; [@B101]; [@B15]; [@B112]).

  **Database**                                           **'Omics data**   **Additional information**   **References**                                                                                                                                                                                                                                                                                                           
  ------------------------------------------------------ ----------------- ---------------------------- ---------------- -- --- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------
  Catalogue of Somatic Mutations in Cancer (COSMIC)      ×                 ×                                                ×   COSMIC contains data from over 13 million tumor samples, identifying 6 million coding mutations and over 19 million non-coding mutations. This resource collates all genes implicated in cancer through somatic mutation, of which 719 are currently listed.                                     [@B3]; [@B112]
  The Cancer Genome Atlas (TCGA)                         ×                 ×                            ×                   ×   TCGA contains multi omic data for 30 different tumor types. In regards to breast cancer it has enabled confirmation of the existence of the four main breast cancer subtypes, it has identified several novel breast cancer drivers and it has identified potentially druggable novel targets.   [@B115]
  Clinical Proteomic Tumor Analysis Consortium (CPTAC)                                                  ×                       CPTAC contains mass spectrometry-based proteomic analysis of tumors from TCGA. The aim of CPTAC is to create a proteogenomic resource where dysregulated proteins and phosphorylation sites can be identified and potentially connected to genomic alterations.                                  [@B101]
  Proteomics Identification Database (PRIDE)                                                            ×                       PRIDE aims to be a resource for open access sharing of mass spectrometry data, not just across cancer. They currently have over 9200 datasets available, including 297 breast cancer datasets.                                                                                                   [@B60]
  GENIE                                                  ×                                                                      GENIE combines genomic and clinical data in an attempt to associate genomic alterations with phenotypic changes                                                                                                                                                                                  [@B34]
  GXB                                                                      ×                                                    GXB compiles immunological transcriptomic data                                                                                                                                                                                                                                                   [@B109]
  Genomic Expression Omnibus (GEO)                       ×                 ×                                                ×   GEO is a database of transcriptomic and epigenomic data                                                                                                                                                                                                                                          [@B18]
  Human Proteome Organization (HUPO)                                                                    ×                       The human proteome project, run by HUPO aims to identify all the proteins in the human proteome and to begin to assess their functionalities and interactions                                                                                                                                    [@B92]
  Transciptome Alterations in Cancer Omnibus (TACCO)                       ×                                                    TACCO is a resource for identifying differentially regulated transcripts within different cancer types and combining these with survival data to determine prognosis based ongene expression profiles                                                                                            [@B15]

G, genomics; T, transcriptomics; P, proteomics; M, metabolomics; E, epigenomics.

The implementation of 'omics approaches in clinical practice will allow analysis of changes in patients at a global level by improving diagnosis and choice of therapeutic plan so far based on a few markers. We predict that 'omics technologies-guided biomarker identification will allow early tumor detection so that treatments can start earlier and that the identification of novel targets will decrease reliance on non-targeted therapies, thus improving the quality of life for breast cancer patients.
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